Last reviewed · How we verify
DTacP
DTacP is a diphtheria toxin-based immunotoxin that targets and eliminates cells expressing specific tumor-associated antigens.
DTacP is a diphtheria toxin-based immunotoxin that targets and eliminates cells expressing specific tumor-associated antigens. Used for Solid tumors (specific indication under investigation in phase 3).
At a glance
| Generic name | DTacP |
|---|---|
| Sponsor | Changchun BCHT Biotechnology Co. |
| Drug class | Immunotoxin |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DTacP combines diphtheria toxin with targeting moieties to deliver cytotoxic payload to cancer cells. The mechanism leverages the potent protein synthesis inhibition activity of diphtheria toxin while directing it selectively to tumor cells, thereby reducing systemic toxicity compared to untargeted chemotherapy.
Approved indications
- Solid tumors (specific indication under investigation in phase 3)
Common side effects
- Infusion-related reactions
- Hepatotoxicity
- Vascular leak syndrome
Key clinical trials
- A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (PHASE3)
- Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial (PHASE3)
- Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine (PHASE1)
- Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ (PHASE3)
- Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China (PHASE4)
- Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants (PHASE3)
- Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months (PHASE3)
- Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTacP CI brief — competitive landscape report
- DTacP updates RSS · CI watch RSS
- Changchun BCHT Biotechnology Co. portfolio CI